NASDAQ:CLLS

Cellectis S.A. Stock Insider Trading

NASDAQ Stock Exchange > Healthcare > Biotechnology

$1.53

+0.0200 (+1.32%)

At Close: Apr 25, 2025

Cellectis S.A. Stock Insider Power

Based on the 0 latest insides trades, we have calculated the insider power to be negative at 0. In total, the insiders bought 0 and sold 0 CLLS shares in the last 0 trades.

Historical Insider Trades

There is currently no insider trading information for this ticker.

However, we invite you to learn more about this term and how to use this knowledge to benefit your trading strategy:

Sorry! Image not available at this moment

ABOUT CELLECTIS S.A.

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALL...

Read Full Profile Here

GOLDEN STAR

Ticker	Change	Signal Date
ALLE $126.46	7.93%	Apr 23
EW $70.46	7.92%	Apr 23
ADSK $261.14	3.37%	Apr 22
AN $165.78	5.62%	Apr 17
BAH $108.78	9.94%	Apr 11

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by